Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. (OTC: ELTP) is a specialty pharmaceutical company engaged in the development, manufacture, and commercialization of generic and specialty oral solid dosage pharmaceutical products, with a particular focus on controlled-release formulations and abuse-deterrent opioid products manufactured at its FDA-registered facility in Northvale, New Jersey. According to its website at elitepharma.com, the company operates as both a pharmaceutical manufacturer producing products for its own commercial portfolio and as a contract development and manufacturing organization (CDMO) providing development and manufacturing services to other pharmaceutical companies seeking a partner with controlled-release drug delivery expertise and demonstrated FDA compliance capabilities. Elite's dual business model generates commercial product revenues alongside recurring CDMO contract revenues that provide operational diversification.
Elite Pharmaceuticals' proprietary pharmaceutical development capabilities, described at elitepharma.com, center on controlled-release drug delivery technologies that modify the rate, timing, and location of drug release in the body to achieve therapeutic advantages over immediate-release formulations — including longer dosing intervals, more consistent drug blood levels, and reduced side effects associated with peak concentration spikes. The company's abuse-deterrent opioid formulation capabilities address a significant public health priority, developing opioid products with physical and chemical properties designed to deter common methods of prescription opioid abuse including crushing, chewing, dissolving, and injection. Elite's FDA-registered manufacturing facility is equipped for the production of controlled substances under DEA Schedule II through V, providing a comprehensive capability set for both its own products and CDMO clients requiring controlled substance manufacturing expertise.
Elite Pharmaceuticals' commercial product portfolio includes generic versions of established branded pharmaceutical products as well as proprietary controlled-release and abuse-deterrent formulations developed by Elite's pharmaceutical sciences team. According to elitepharma.com, the company's CDMO business serves both large pharmaceutical companies seeking controlled-release manufacturing partners and smaller specialty pharmaceutical companies that require FDA-compliant manufacturing capabilities without the capital investment of building their own production infrastructure. Elite's combination of controlled-release formulation expertise, abuse-deterrent opioid development capabilities, FDA-registered manufacturing facility, DEA Schedule II through V manufacturing authorization, and dual commercial and CDMO business model positions it as a specialized and experienced participant in the specialty pharmaceutical manufacturing market.